Abstracts tagged "anti-TNF therapy"

Abstract Number: 2768 • 2015 ACR/ARHP Annual Meeting
Trend and Factors Associated with Switching Treatment after Initial Anti-TNF Therapy Among Patients with Rheumatoid Arthritis
Wenhui Wei¹, Emma Sullivan², Chieh-I Chen³, James Piercy² and Stuart Blackburn², ¹Sanofi-Aventis, Bridgewater, NJ, ²Adelphi Real World, Manchester, United Kingdom, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Among rheumatoid arthritis (RA) patients who progress beyond their first biologic disease-modifying antirheumatic drug (bDMARD), in-class cycling between different tumor necrosis factor inhibitors (TNFi)…
Abstract Number: 2893 • 2015 ACR/ARHP Annual Meeting
Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis after 16 Weeks of Golimumab Treatment
Walter Maksymowych¹, Sean P. Curtis², Maxime Dougados³, Gina Bergman², Susan Huyck², Anjela Tzontcheva² and Joachim Sieper⁴, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Merck & Co., Inc., Kenilworth, NJ, ³Paris-Descartes University, Paris, France, ⁴University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: Chronic inflammation, back pain, and progressive spinal stiffness associated with axial spondyloarthritis (axSpA) can decrease quality of life (QoL). The purpose of this study…
Abstract Number: 456 • 2015 ACR/ARHP Annual Meeting
Disease and Treatment Characteristics That Might Influence Long-Term Retention with Biologics in the Real-World Clinical Setting: Experience from the Rhumadata Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui³, Jean-Pierre Raynauld¹, Diane Sauvageau¹, Angèle Turcotte⁴, Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Institut de Rhumatologie, Montreal, QC, Canada, ⁴Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada
Disease and Treatment Characteristics that Might Influence Long-term Retention with Biologics in the Real-world Clinical Setting: Experience from the Rhumadata Clinical Database and Registry Background/Purpose:…
Abstract Number: 712 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Anti-TNF Treatment in a Longitudinally Followed Ankylosing Spondylitis (AS) Cohort
Mary Gibson¹, MinJae Lee², Michael M. Ward³, Lianne S. Gensler⁴, Matthew A. Brown⁵, Shervin Assassi⁶, Colton Pence¹, Laura A. Diekman⁷, Mohammad H. Rahbar⁸, Michael H. Weisman⁹ and John D. Reveille¹, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁷Rheumatology, University of Texas Medical School, Houston, TX, ⁸The University of Texas Health Science Center at Houston, Houston, TX, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: TNF-α inhibitor therapy is recommended by ASAS/EULAR guidelines for ankylosing spondylitis (AS) patients with moderate-to-high disease activity despite inadequate response to NSAIDs in addition…
Abstract Number: 1722 • 2015 ACR/ARHP Annual Meeting
What Is the Clinical Utility of MR Imaging in the Management of Nr-Axspa Patients?
Ismail Sari¹, Ahmed Omar¹, Jonathan Chan², Mohamed Bedaiwi¹, Renise Ayearst¹, Nigil Haroon¹ and Robert D Inman³, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Spondylitis program, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Immunlogy and Institute of Medical Science, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: The ASAS classification criteria have provided new insights in the classification of axial spondyloarthropathy (axSpA). MR imaging (MRI) is an intrinsic component of the…
Abstract Number: 2769 • 2015 ACR/ARHP Annual Meeting
Factors Associated with TNF Switching: a Retrospective Real-World Study of Patients with Rheumatoid Arthritis
Wenhui Wei¹, Keith Knapp², Li Wang³, Chieh-I Chen⁴, Gary Craig², Karen Ferguson² and Sergio Schwartzman⁵, ¹Sanofi-Aventis, Bridgewater, NJ, ²Discus Analytics, Inc., Spokane, WA, ³Director, Analytic Research, STATinMED Research, Plano, TX, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Switching of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patient treatment is common in real-world clinical practice. The context for why patients switch…
Abstract Number: 3113 • 2015 ACR/ARHP Annual Meeting
Interest of Assessing Anti-Drug Antibodies for the Choice Between a Second Anti-TNF and a Non-TNF-Targeted Biologic in Patients with Inadequate Response to a First Anti-TNF : Results from the Randomized Controlled Trial « Rotation or Change »
Sophie Candon¹, Lucienne Chatenoud¹, Olivier Brocq², Aleth Perdriger³, Slim Lassoued⁴, Jean-Marie Berthelot⁵, Daniel Wendling⁶, Liana Euller-Ziegler⁷, Martin Soubrier⁸, Christophe Richez⁹, Bruno Fautrel¹⁰, Arnaud Constantin¹¹, Xavier Mariette¹², Jacques Morel¹³, Mélanie Gilson¹⁴, Gregoire Cormier¹⁵, Jean Hugues Salmon¹⁶, Stephanie Rist Bouillon¹⁷, Frederic Liote¹⁸, Hubert Marotte¹⁹, Christine Bonnet²⁰, Christian Marcelli²¹, Jeremie Sellam¹, Olivier Meyer²², Elisabeth Solau-Gervais²³, Sandrine Guis²⁴, Jean Marc Ziza²⁵, Charles Zarnitsky²⁶, Isabelle Chary-Valckenaere²⁷, O Vittecoq²⁸, Alain Saraux²⁹, Yves-Marie Pers³⁰, Martine Gayraud³¹, Gilles Bolla³², Pascal Claudepierre³³, Marc Ardizzone³⁴, Emmanuelle Dernis Labous³⁵, Maxime A. Breban³⁶, Olivier Fain³⁷, Jean Charles Balblanc³⁸, Elodie Perrodeau³⁹, Jean Sibilia⁴⁰, Philippe Ravaud³¹ and Jacques Gottenberg⁴¹, ¹Rheumatology, PARIS, France, ²Hospital Center Princesse Grâce, Monaco, Monaco, ³Service de Rhumatologie, CHU de Rennes, Rennes, France, ⁴Rheumatology, Cahors, France, ⁵Rheumatology, University Hospital, Nantes, France, ⁶Université de Franche-Comté, Besançon, France, ⁷Rheumatology, Nice, France, ⁸Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁹Rheumatology, Bordeaux, France, ¹⁰Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ¹¹Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ¹²Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ¹³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ¹⁴Hospital Center, Grenoble, France, ¹⁵Rheumatology, La Roche Sur Yon, France, ¹⁶Hôpital Maison Blanche, Rheumatology, REIMS, France, ¹⁷Rhumatologie, Hopital La Source, La Source, France, ¹⁸Rheumatology, Lariboisière, France, ¹⁹INSERM 1059 / LBTO, Université de Lyon, Saint-Etienne; Rheumatology Department, Saint-Etienne, France, ²⁰Rheumatology, CHU Dupuytren, Limoges, France, ²¹Rheumatology, Caen, France, ²²Rheumatology, Hopital Bichat, Paris, France, ²³Rhumatologie, University Hospital, Poitiers, France, ²⁴Rheumatology, Marseille, France, ²⁵Hopital Croix-Saint-Simon, Paris Cedex 20, France, ²⁶Rheumatology, Le Havre, France, ²⁷CHU de Nancy, Rheumatology, Nancy, France, ²⁸University Hospital, Rouen, France, ²⁹Rheumatology, Brest, France, ³⁰Rheumatology, Montpellier, France, ³¹Rheumatology, Paris, France, ³²Rheumatology, Cannes, France, ³³Rheumatology, Université Paris Est Créteil, Créteil, France, ³⁴Rheumatology, Centre Hospitalier de Mulhouse, Mulhouse, France, ³⁵Réseau Hôpital et Ville en Rhumatologie (RHEVER) Network, Paris, France, ³⁶Rheumatology, A. Paré University Hospital, Boulogne-Billancourt, France, ³⁷Internal Medicine Department, Saint Antoine Hospital, Paris, France, ³⁸Rheumatology, Belffort, France, ³⁹Epidemiologist, Paris, France, ⁴⁰Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴¹Hautepierre, Strasbourg, France
Background/Purpose: Anti-drug antibodies (ADAs) might result in loss of efficacy to anti-TNF. The impact of ADAs to a 1st anti-TNF on subsequent response to a…
Abstract Number: 488 • 2015 ACR/ARHP Annual Meeting
Six-Year Retention Rates with Abatacept Vs TNF Inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-World Rhumadata Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui³, Jean-Pierre Raynauld¹, Diane Sauvageau¹, Angèle Turcotte⁴, Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Université de Montréal, Montreal, QC, Canada, ⁴Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: The sustainability of any regimen is an important factor to consider when selecting therapy for chronic conditions, such as rheumatoid arthritis (RA). Recent reports…
Abstract Number: 968 • 2015 ACR/ARHP Annual Meeting
Certolizumab Pegol in Combination with Methotrexate in DMARD-Naïve Patients with Active, Severe, Progressive Rheumatoid Arthritis: Results from a Randomized, Double-Blind, Controlled Phase 3 Study
Michael Weinblatt¹, Clifton Bingham², Gerd Burmester³, VP Bykerk⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Désirée van der Heijde⁷, Daljit Tatla⁸, Catherine Arendt⁹, Irina Mountian¹⁰, Brenda VanLunen¹¹ and Paul Emery¹², ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ⁷University Hospital, Maastricht, Netherlands, ⁸8010 Arco Corporate Dr, UCB Pharma, Raleigh, NC, ⁹Global Medical Affairs, UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Early stages of rheumatoid arthritis (RA) may provide a therapeutic window in which biologic agents are most effective.1 C-EARLY (NCT01519791) is a phase 3…
Abstract Number: 1731 • 2015 ACR/ARHP Annual Meeting
Radiographic Damage of Facet Joints and Vertebral Bodies in the Cervical Spine in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors
Fiona Maas¹, Suzanne Arends¹, Elisabeth Brouwer¹, Eveline van der Veer², Hendrika Bootsma¹, Rizwana Chaudhry¹, Monique Efde³, Freke Wink³ and Anneke Spoorenberg¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: In ankylosing spondylitis (AS), syndesmophyte formation and ankylosis of the vertebral bodies are characteristic radiographic changes that are evaluated during follow-up. However, the facet…
Abstract Number: 2835 • 2015 ACR/ARHP Annual Meeting
Long-Term Improvements with Certolizumab Pegol in Joints and Extra-Articular Manifestations of Psoriatic Arthritis in Patients with and without Prior Anti-TNF Exposure
Dafna D. Gladman¹, Alice B. Gottlieb², Bengt Hoepken³, Luke Peterson⁴ and Oliver FitzGerald⁵, ¹Toronto Western Research Institute, Toronto, ON, Canada, ²Dermatology, Tufts Medical Center, Boston, MA, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Raleigh, NC, ⁵Department of Rheumatology, St. Vincent’s University Hospital, UCD School of Medicine and Medical Sciences and Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: Previous reports of RAPID-PsA (NCT01087788) have demonstrated the efficacy of certolizumab pegol (CZP) in patients (pts) with psoriatic arthritis (PsA) over 96 weeks (wks),1…
Abstract Number: 3196 • 2015 ACR/ARHP Annual Meeting
Predictive Biomarkers for Response or Non-Response to MTX Monotherapy in Early RA
Karen Hambardzumyan¹, Rebecca J. Bolce², Saedis Saevarsdottir³, Kristina Forslind^4,5, Johan A Karlsson⁶ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ⁴Departments of Rheumatology, Helsingborgs Hospital and University of Lund, Helsingborg and Lund, Sweden, ⁵Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: In early rheumatoid arthritis (eRA), a clinically significant proportion of patients may respond to first-line treatment with methotrexate (MTX). A priori identification of patients…
Abstract Number: 505 • 2015 ACR/ARHP Annual Meeting
Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Certolizumab, Etanercept, Infliximab, Rituximab and Tocilizumab in a Real World Routine Care Registry
Yusuf Yazici¹, Hannah Bernstein¹ and Christopher Swearingen², ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Pediatrics & Biostatistics, University of Arkansas, Little Rock, AR
Background/Purpose: With the availability of multiple biologic agents, each with different modes of action, use of real world registries provide the manner in which to…
Abstract Number: 973 • 2015 ACR/ARHP Annual Meeting
The Effect of TNF Inhibitor Treatment on Occurrence of Anterior Uveitis in Ankylosing Spondylitis: Results from the Swedish Biologics Register
Elisabeth Lie^1,2, Ulf Lindström², Tatiana Zverkova-Sandström², Inge C Olsen¹, Helena Forsblad-d'Elia³, Johan Askling⁴, Lars Erik Kristensen^5,6 and Lennart TH Jacobsson², ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ³Departments of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁴Clinical Epidemiology Unit & Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Musculoskeletal Statistics Unit, The Parker Institute, Dept. of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁶Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden
Background/Purpose: Anterior uveitis is a relatively frequent extra-articular manifestation in ankylosing spondylitis (AS), with a prevalence of 25.8% in a recent meta-analysis. TNF inhibitor (TNFi)…
Abstract Number: 1732 • 2015 ACR/ARHP Annual Meeting
Slow Spinal Radiographic Progression in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors
Fiona Maas¹, Suzanne Arends¹, Ivette Essers², Elisabeth Brouwer¹, Eveline van der Veer³, Freke Wink⁴, Monique Efde⁴, Hendrika Bootsma¹ and Anneke Spoorenberg¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: Assessing radiographic progression in ankylosing spondylitis (AS) is challenging. The results regarding the effect of tumor necrosis factor-alpha (TNF-α) blocking therapy on spinal radiographic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].